Supplementation with carnosine decreases plasma triglycerides andmodulates atherosclerotic plaque composition in diabetic apoE-/- mice

Atherosclerosis

Volumn 232, Issue 2, 2014, Pages 403-409

  Brown, Bronwyn E ^a,c   Kim, Christine H J ^a   Torpy, Fraser R ^b   Bursill, Christina A ^a   McRobb, Lucinda S ^a,d   Heather, Alison K ^a,b   Davies, Michael J ^a,c   Van Reyk, David M ^b  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^c University of Sydney   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Atherosclerosis; Carnosine; Cholesterol; Diabetes; Triglycerides

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; APOLIPOPROTEIN E; CARNOSINE; CHOLESTEROL; COLLAGEN; DRINKING WATER; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; STREPTOZOCIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SINUS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BODY MASS; BRACHIOCEPHALIC TRUNK; CELL COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETOGENESIS; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HYPERGLYCEMIA; HYPERLIPIDEMIA; LONG TERM CARE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; CARNOSINE; CHOLESTEROL; DIABETES; TRIGLYCERIDES;

ANIMALS; AORTA; APOLIPOPROTEINS E; BLOOD GLUCOSE; BRACHIOCEPHALIC TRUNK; CARNOSINE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIETARY SUPPLEMENTS; HEMOGLOBINS; HYPERTRIGLYCERIDEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIVARIATE ANALYSIS; PLAQUE, ATHEROSCLEROTIC; TRIGLYCERIDES;

EID: 84892846912     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.11.068     Document Type: Article

References (30)

1. Bianchi C., Miccoli R., Daniele G., Penno G., Del Prato S. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. Diabetes Care 2009, 32(Suppl.2):S342-S348.
2. Hsueh W.A., Abel E.D., Breslow J.L., et al. Recipes for creating animal models of diabetic cardiovascular disease. Circ Res 2007, 100:1415-1427.
3. Jandeleit-Dahm K., Cooper M.E. The role of AGEs in cardiovascular disease. Curr Pharm Des 2008, 14:979-986.
4. Boldyrev A.A., Aldini G., Derave W. Physiology and pathophysiology of carnosine. Physiol Rev 2013, 93:1803-1845.
5. Hipkiss A.R. Carnosine and its possible roles in nutrition and health. Adv Food Nutr Res 2009, 57:87-154.
6. Barski O.A., Xie Z., Baba S.P., et al. Dietary carnosine prevents early atherosclerotic lesion formation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2013, 33:1162-1170.
7. Rashid I., van Reyk D.M., Davies M.J. Carnosine and its constituents inhibit glycation of low-density lipoproteins that promote foam cell formation invitro. FEBS Lett 2007, 581:1067-1070.
8. Menini S., Iacobini C., Ricci C., et al. D-carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a Western diet through reduction of carbonyl stress and inflammation. Br J Pharmacol 2012, 166:1344-1356.
9. Mong M.-C., Chao C.-Y., Yin M.-C. Histidine and carnosine alleviated hepatic steatosis in mice consumed high saturated fat diet. Eur J Pharmacol 2011, 653:82-88.
10. Stvolinsky S.L., Bulygina E.R., Fedorova T.N., et al. Biological activity of novel synthetic derivatives of carnosine. Cell Mol Neurobiol 2010, 30:395-404.
11. Aldini G., Orioli M., Rossoni G., et al. The carbonyl scavenger carnosine ameliorates dyslipidemia and renal function in zucker obese rats. JCell Mol Med 2011, 15:1339-1356.
12. Lee Y.-T., Hsi C.-C., Lin M.-H., Liu K.-S., Yin M.-C. Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. Eur J Pharmacol 2005, 513:145-150.
13. Candido R., Jandeleit-Dahm K.A., Cao Z., et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002, 106:246-253.
14. McRobb L., Handelsman D.J., Heather A.K. Androgen-induced progression of arterial calcification in apolipoprotein E-null mice is uncoupled from plaque growth and lipid levels. Endocrinology 2009, 150:841-848.
15. Pattison D.I., Hawkins C.L., Davies M.J. Hypochlorous acid-mediated protein oxidation: how important are chloramine transfer reactions and protein tertiary structure?. Biochemistry 2007, 46:9853-9864.
16. Ali Z.A., Bursill C.A., Hu Y., et al. Gene transfer of a broad spectrum CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice. Circulation 2005, 112:I-235-I-241.
17. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998, 4:1025-1031.
18. Candido R., Allen T.J., Lassila M., et al. Irbesartan but not amlidipine suppresses diabetes-associated atherosclerosis. Circulation 2004, 109:1536-1542.
19. Nestel P., Fujii A., Allen T. The cis-9,trans-11 isomer of conjugated linoleic acid (CLA) lowers plasma triglyceride and raises HDL cholesterol concentrations but does not suppress aortic atherosclerosis in diabetic apoE-deficient mice. Atherosclerosis 2006, 189:282-287.
20. Yamano T., Niijima A., Iimori S., Tsuruoka N., Kiso Y., Nagai K. Effect of l-carnosine on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats. Neurosci Lett 2001, 313:78-82.
21. Levi Z., Shaish A., Yacov N., et al. Rosiglitazone (PPAR-γ-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Diabetes Obes Metab 2003, 5:45-50.
22. Small D.M., Shipley G.G. Physical-chemical basis of lipid deposition in atherosclerosis. Science 1974, 185:222-229.
23. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868.
24. Reimers G.J., Jackson C.L., Rickards J., et al. Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I. Cardiovasc Res 2011, 91:37-44.
25. Davies M.J. The oxidative environment and protein damage. Biochim Biophys Acta 2005, 1703:93-109.
26. Gebicki S., Bartosz B., Gebicki J.M. Peroxidation of proteins by free radicals and its consequences to living organisms. Curr Topics Biophys 1995, 1995:220-226.
27. Lo T.W.C., Selwood T., Thornalley P.J. The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochem Pharmacol 1994, 48:1865-1870.
28. Requena J.R., Fu M.-X., Ahmed M.U., et al. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidised human low-density lipoprotein. Biochem J 1997, 322:317-325.
29. Hoff H.F., O'Neil J., Chisolm G.D., et al. Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis 1989, 9:538-549.
30. Ishii T., Itoh K., Ruiz E., et al. Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ Res 2004, 94:609-616.